Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 3/20 | 0.67 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.60 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.59 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.59 |
| ▸ | KIT | P10721 | 1/20 | 0.55 |
| ▸ | MET | P08581 | 2/20 | 0.53 |
| ▸ | KDR | P35968 | 2/20 | 0.53 |
| ▸ | MST1R | Q04912 | 1/20 | 0.53 |
| ▸ | SRC | P12931 | 1/20 | 0.52 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.52 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30388215 | 0.99 | AXL (0.66) | AXLFGFR2PDGFRAPDGFRBKIT | |
| Hydrochloric Acid SCHEMBL21776567 | 0.99 | AXL (0.66) | AXLFGFR2PDGFRAPDGFRBKIT | |
| SCHEMBL17035605 | 0.99 | AXL (0.66) | AXLFGFR2PDGFRAPDGFRBKIT | |
| SCHEMBL17035604 | 0.97 | AXL (0.64) | AXLFGFR2PDGFRAPDGFRBKIT | |
| SCHEMBL23456877 | 0.92 | AXL (0.59) | AXLFGFR2PDGFRAPDGFRBKIT | |
| SCHEMBL14966993 | 0.91 | AXL (0.69) | AXLFGFR2PDGFRAPDGFRBMET | |
| SCHEMBL31554454 | 0.91 | AXL (0.69) | AXLFGFR2PDGFRAPDGFRBMET | |
| SCHEMBL1591164 | 0.91 | AXL (0.72) | AXLFGFR2PDGFRAPDGFRBKIT | |
| SCHEMBL14821391 | 0.90 | AXL (0.57) | AXLFGFR2PDGFRAPDGFRBKIT | |
| SCHEMBL4575949 | 0.90 | AXL (0.57) | AXLFGFR2PDGFRAPDGFRBKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 316 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522902-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2016-12-20 | — | — | US | claimed |
| EP-2780338-B1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | IGNYTA INC (US) | 2016-11-09 | — | — | EP | claimed |
| US-9206130-B2 | Quinoline derivatives as AXL kinase inhibitors | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-12-08 | — | — | US | claimed |
| US-9120778-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2015-09-01 | — | — | US | claimed |
| US-20150209358-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. | 2015-07-30 | — | — | US | claimed |
| US-20150210670-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. | 2015-07-30 | — | — | US | claimed |
| US-20140275077-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. (US) | 2014-09-18 | — | — | US | claimed |
| WO-2009017838-A2 | COMBINATIONS OF JAK-2 INHIBITORS AND OTHER AGENTS | EXELIXIS, INC. (US) | 2009-02-05 | — | — | WO | claimed |
| EP-4294804-B1 | PYRIDONE COMPOUNDS AND METHODS OF USE | EXELIXIS INC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12497394-B2 | Fused-cyclic pyrazolone formamide compound and preparation method therefor, pharmaceutical composition and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2025-12-16 | — | — | US | disclosed |
| US-12371428-B2 | Pyridone compounds and methods of use | EXELIXIS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| WO-2025105857-A1 | HETEROARYL-DERIVATIVE COMPOUND AND USE THEREOF | (주)신테카바이오 | 2025-05-22 | — | — | WO | disclosed |
| WO-2025105858-A1 | HETEROARYL-DERIVATIVE COMPOUND AND USE THEREOF | (주)신테카바이오 | 2025-05-22 | — | — | WO | disclosed |
| EP-4552695-A2 | TYROSINE KINASES INHIBITORS AND USES THEREOF | Great Novel Therapeutics Biotech & Medicals Corporation (TW) | 2025-05-14 | — | — | EP | disclosed |
| US-20040229876-A1 | Quinoline derivatives and quinazoline derivatives having azolyl group | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-11-18 | — | — | US | disclosed |
| US-20040132727-A1 | Quinoline and quinazoline derivatives and drugs containing the same | KIRIN HOLDINGS KABUSHIKI KAISHA (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-1411046-A1 | QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF−PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-04-21 | — | — | EP | disclosed |
| EP-1382604-A1 | QUINOLINE DERIVATIVE HAVING AZOLYL GROUP AND QUINAZOLINE DERIVATIVE | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-01-21 | — | — | EP | disclosed |
| US-20030087907-A1 | Quinoline derivatives and quinazoline derivatives having azolyl group | KIRIN BEER KABUSHIKI KAISHA (JP) | 2003-05-08 | — | — | US | disclosed |
| EP-1243582-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES AND DRUGS CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2002-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371428-B2 | Pyridone compounds and methods of use | PDXK, PLK2, MAP4K2 | AXL 1100/4885FGFR2 3433/4885PDGFRA 1935/4885 |
| US-20040132727-A1 | Quinoline and quinazoline derivatives and drugs containing the same | PDGFRA, PDGFRB, PDGFA | AXL 99/4885FGFR2 78/4885PDGFRA 1/4885 |
| US-20150210670-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | AXL, RET, BRAF | AXL 1/4885FGFR2 201/4885PDGFRA 103/4885 |
| US-20140275077-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | AXL, RET, BRAF | AXL 1/4885FGFR2 201/4885PDGFRA 103/4885 |
| US-20040229876-A1 | Quinoline derivatives and quinazoline derivatives having azolyl group | NQO2, H1-5, NRAS | AXL 1464/4885FGFR2 4033/4885PDGFRA 4104/4885 |
| US-12497394-B2 | Fused-cyclic pyrazolone formamide compound and preparation method therefor, pharmaceutical composition and use thereof | AXL, WEE1, FLT3 | AXL 1/4885FGFR2 61/4885PDGFRA 236/4885 |
| US-20030087907-A1 | Quinoline derivatives and quinazoline derivatives having azolyl group | NQO2, H1-5, NRAS | AXL 1464/4885FGFR2 4033/4885PDGFRA 4104/4885 |
| US-20150209358-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | AXL, RET, BRAF | AXL 1/4885FGFR2 201/4885PDGFRA 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.